Yahoo Finance11d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
BioSpace10d
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
FoodNavigator1mon
Is this GLP-1.2? New generation of weight-loss drugs moving in
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...
Morningstar11d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...